The evolving story of the RAAS in hypertension, diabetes and CV disease - Moving from macrovascular to microvascular targets

Fundamental and Clinical Pharmacology

Volumn 23, Issue 6, 2009, Pages 693-703

  Steckelings, Ulrike Muscha ^a   Rompe, Franziska ^a   Kaschina, Elena ^a   Unger, Thomas ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Diabetes; Diabetic microvascular disease; Renin angiotensin system

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANGIOTENSIN 1 RECEPTOR; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HEXOSAMINE; INDAPAMIDE PLUS PERINDOPRIL; LISINOPRIL; LOSARTAN; PLACEBO; POLYOL; PROTEIN KINASE C;

APOPTOSIS; ARTERY DISEASE; ATHEROSCLEROSIS; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CELL DAMAGE; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; ENZYME ACTIVATION; FIBROSIS; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY INJURY; MICROVASCULARIZATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETINA INJURY; REVIEW; SIGNAL TRANSDUCTION; TISSUE INJURY; WOUND HEALING;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIABETIC RETINOPATHY; HUMANS; HYPERTENSION; RECEPTOR, ANGIOTENSIN, TYPE 1; RENIN-ANGIOTENSIN SYSTEM;

EID: 70449484613     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2009.00780.x     Document Type: Review

References (107)

1. Liang P., Jones C.A., Bisgrove B.W. et al. Genomic characterization and expression analysis of the first nonmammalian renin genes from zebrafish and pufferfish. Physiol. Genomics (2004) 16 314 322.
2. Steckelings U.M., Unger T., The renin-angiotensin-aldosterone system, in : Mancia G., Grassi G., Kjeldsen S. (Eds Manual of Hypertension of The European Society of Hypertension. Informa HealthCare, London, UK, 2008, vol 14, pp. 110 116.
3. Tigerstedt R., Bergman P.G. Niere und Kreislauf. Skand. Arch. Physiol. (1898) 8 223 271.
4. Braun-Menendez E., Fasciolo J.C., Leloir L.F., Munoz J.M. The substance causing renal hypertension. J. Physiol. (1940) 98 283 298.
5. Page I.H., Helmer O.M. A cristalline pressor substance (angiotonin) resulting from the reaction between renin and renin activator. J. Exp. Med. (1940) 71 29 42.
6. Skeggs L.T. Jr., Marsh W.H., Kahn J.R., Shumway N.P. The existence of two forms of hypertensin. J. Exp. Med. (1954) 99 275 282.
7. Ganten D., Minnich J.L., Granger P. et al. Angiotensin-forming enzyme in brain tissue. Science (1971) 173 64 65.
8. Chiu A.T., Herblin W.F., Ardecky R.J. et al. Identification of angiotensin II receptor subtypes. Biochem. Biophys. Res. Commun. (1989) 165 196 203.
9. Whitebread S., Mele M., Kamber B., de Gasparo M. Preliminary biochemical characterization of two angiotensin II receptor subtypes. Biochem. Biophys. Res. Commun. (1989) 163 284 291.
10. Speth R.C., Kim K.H. Discrimination of two angiotensin II receptor subtypes with a selective agonist analogue of angiotensin II p-aminophenylalanine8 angiotensin II. Biochem. Biophys. Res. Commun. (1990) 169 997 1006.
11. Stoll M., Steckelings U.M., Paul M., Bottari S.P., Metzger R., Unger T. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J. Clin. Invest. (1995) 95 651 657.
12. Paul M., Poyan Mehr A., Kreutz R. Physiology of local renin-angiotensin systems. Physiol. Rev. (2006) 86 747 803.
13. de Gasparo M., Catt K.J., Inagami T., Wright J.W., Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol. Rev. (2000) 52 415 472.
14. Price D.A., Porter L.E., Gordon M. et al. The paradox of the low-renin state in diabetic nephropathy. J. Am. Soc. Nephrol. (1999) 10 2382 2391.
15. Franken A.A., Derkx F.H., Schalekamp M.A. et al. Association of high plasma prorenin with diabetic retinopathy. J. Hypertens. Suppl. (1988) 6 S461 S463.
16. Luetscher J.A., Kraemer F.B., Wilson D.M., Schwartz H.C., Bryer-Ash M. Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications. N. Engl. J. Med. (1985) 312 1412 1417.
17. Ichihara A., Hayashi M., Kaneshiro Y. et al. Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin. J. Clin. Invest. (2004) 114 1128 1135.
18. Schefe J.H., Menk M., Reinemund J. et al. A novel signal transduction cascade involving direct physical interaction of 30 the renin/prorenin receptor with the transcription factor promyelocytic zinc finger protein. Circ. Res. (2006) 99 1355 1366.
19. Toma I., Kang J.J., Sipos A. et al. Succinate receptor GPR91 provides a direct link between high glucose levels and renin release in murine and rabbit kidney. J. Clin. Invest. (2008) 118 2526 2534.
20. Choi K.C., Kim N.H., An M.R., Kang D.G., Kim S.W., Lee J. Alterations of intrarenal renin-angiotensin and nitric oxide systems in streptozotocin-induced diabetic rats. Kidney Int. Suppl. (1997) 60 S23 S27.
21. Hsieh T.J., Fustier P., Zhang S.L. et al. High glucose stimulates angiotensinogen gene expression and cell hypertrophy via activation of the hexosamine biosynthesis pathway in rat kidney proximal tubular cells. Endocrinology (2003) 144 4338 4349.
22. Lavrentyev E.N., Malik K.U. High glucose-induced Nox1-derived superoxides downregulate PKC-II, which subsequently decreases ACE2 expression and ANG(1-7) formation in rat VSMCs. Am. J. Physiol. Heart Circ. Physiol. (2009) 296 106 118.
23. Bonnet F., Candido R., Carey R.M. et al. Renal expression of angiotensin receptors in long-term diabetes and the effects of angiotensin type 1 receptor blockade. J. Hypertens. (2002) 20 1615 1624.
24. Xu B., Chiu J., Feng B., Chen S., Chakrabarti S. PARP activation and the alteration of vasoactive factors and extracellular matrix protein in retina and kidney in diabetes. Diabetes Metab. Res. Rev. (2008) 24 404 412.
25. Reinemund J., Seidel K., Steckelings U.M. et al. Poly(ADP-ribose) polymerase-1 (PARP-1) transcriptionally regulates angiotensin AT2 receptor (AT2R) and AT2R binding protein (ATBP) genes. Biochem. Pharmacol. (2009) 12 1795 1805.
26. Carey R.M., Siragy H.M. The intrarenal renin-angiotensin system and diabetic nephropathy. Trends Endocrinol. Metab. (2003) 14 274 281.
27. Ebrahimian T.G., Tamarat R., Clergue M., Duriez M., Levy B.I., Silvestre J.S. Dual effect of angiotensin-converting enzyme inhibition on angiogenesis in type 1 diabetic mice. Arterioscler. Thromb. Vasc. Biol. (2005) 25 65 70.
28. Danser A.H., van den Dorpel M.A., Deinum J. et al. Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy. J. Clin. Endocrinol. Metab. (1989) 68 160 167.
29. Danser A.H., Derkx F.H., Admiraal P.J., Deinum J., de Jong P.T., Schalekamp M.A. Angiotensin levels in the eye. Invest. Ophthalmol. Vis. Sci. (1994) 35 1008 1018.
30. Funatsu H., Yamashita H., Ikeda T., Nakanishi Y., Kitano S., Hori S. Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders. Am. J. Ophthalmol. (2002) 133 537 543. (Pubitemid 34258063)
31. Carey R.M., Siragy H.M. The intrarenal renin-angiotensin system and diabetic nephropathy. Trends Endocrinol. Metab. (2003) 14 274 281.
32. Anderson S., Jung F.F., Ingelfinger J.R. Renal renin-angiotensin system in diabetes. functional, immunohistochemical and molecular biological correlations. Am. J. Physiol. (1993) 265 F477 F486.
33. Singh R., Alavi N., Singh A.K., Leehey D.J. Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation. Diabetes (1999) 48 2066 2073.
34. Cooper M.E., Bonnet F., Oldfield M., Jandeleit-Dahm K. Mechanisms of diabetic vasculopathy: an overview. Am. J. Hypertens. (2001) 14 475 486.
35. He Z., Rask-Madsen C., King G.L. Pathogenesis of diabetic microvascular complications, in : De Fronzo R.A., Ferrannini E., Keen H., Zimmet P. (Eds International textbook of diabetes mellitus. John Wiley & Sons, Hoboken, NJ, 2004, 2, pp. 1135 1159.
36. Brownlee M. Banting lecture 2004. The pathobiology of diabetic complications: a unifying mechanism. Diabetes (2005) 54 1615 1625.
37. Nishikawa T., Edelstein D., Du X.L. et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature (2000) 404 787 790.
38. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature (2001) 414 813 820.
39. Stitt A.W., Jenkins A.J., Cooper M.E. Advanced glycation end products and diabetic complications. Expert. Opin. Investig. Drugs (2002) 11 1205 1223.
40. Hammes H.P., Weiss A., Hess S. et al. Modification of vitronectin by advanced glycation alters functional properties in vitro and in the diabetic retina. Lab. Invest. (1996) 75 325 338.
41. Bierhaus A., Chevion S., Chevion M. et al. Advanced glycation end product-induced activation of NF-kappaB is suppressed by alpha-lipoic acid in cultured endothelial cells. Diabetes (1997) 46 1481 1490.
42. Haitoglou C.S., Tsilibary E.C., Brownlee M., Charonis A.S. Altered cellular interactions between endothelial cells and nonenzymatically glucosylated laminin/type IV collagen. J. Biol. Chem. (1992) 267 12404 12407.
43. Xu X., Zhu Q., Xia X., Zhang S., Gu Q., Luo D. Blood-retinal barrier breakdown induced by activation of protein kinase C via vascular endothelial growth factor in streptozotocin-induced diabetic rats. Curr. Eye Res. (2004) 28 251 256.
44. Williams B., Gallacher B., Patel H., Orme C. Glucose-induced protein kinase C activation regulates vascular permeability factor mRNA expression and peptide production by human vascular smooth muscle cells in vitro. Diabetes (1997) 46 1497 1503.
45. Yokota T., Ma R.C., Park J.-Y. et al. Role of protein kinase C on the expression of platelet-derived growth factor and endothelin-1 in the retina of diabetic rats and cultured retinal capillary pericytes. Diabetes (2003) 52 838 845.
46. Feener E.P., Xia P., Inoguchi T., Shiba T., Kunisaki M., King G.L. Role of protein kinase C in glucose- and angiotensin II-induced plasminogen activator inhibitor expression. Contrib. Nephrol. (1996) 118 180 187.
47. Koya D., Jirousek M.R., Lin Y.W., Ishii H., Kuboki K., King G.L. Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J. Clin. Invest. (1997) 100 115 126.
48. Kuboki K., Jiang Z.Y., Takahara N. et al. Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo : a specific vascular action of insulin. Circulation (2000) 101 676 681.
49. Yerneni K.K., Bai W., Khan B.V., Medford R.M., Natarajan R. Hyperglycemia-induced activation of nuclear transcription factor kappa B in vascular smooth muscle cells. Diabetes (1999) 48 855 864.
50. Nagai N., Izumi-Nagai K., Oike Y. et al. Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kappaB pathway. Invest. Ophthalmol. Vis. Sci. (2007) 48 4342 4350.
51. Das Evcimen N., King G.L. The role of protein kinase C activation and the vascular complications of diabetes. Pharmacol. Res. (2007) 55 498 510.
52. Goldberg H.J., Whiteside C.I., Fantus I.G. The hexosamine pathway regulates the plasminogen activator inhibitor-1 gene promoter and Sp1 transcriptional activation through protein kinase C-beta I and -delta. J. Biol. Chem. (2002) 277 33833 33841.
53. Ellis E.A., Grant M.B., Murray F.T. et al. Increased NADH oxidase activity in the retina of the BBZ/Wor diabetic rat. Free Rad. Biol. Med. (1998) 24 111 201.
54. Förstermann U. Oxidative stress in vascular disease: causes, defense mechanisms and potential therapies. Nat. Clin. Pract. Cardiovasc. Med. (2008) 5 338 349.
55. Yamagishi S., Amano S., Inagaki Y. et al. Angiotensin II-type 1 receptor interaction upregulates vascular endothelial growth factor messenger RNA levels in retinal pericytes through intracellular reactive oxygen species generation. Drugs Exp. Clin. Res. (2003) 29 75 80.
56. Chen P., Guo A.M., Edwards P.A., Trick G., Scicli A.G. Role of NADPH oxidase and ANG II in diabetes-induced retinal leukostasis. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2007) 293 1619 1629.
57. Fukumoto M., Takai S., Ishizaki E. et al. Involvement of angiotensin II-dependent vascular endothelial growth factor gene expression via NADPH oxidase in the retina in a type 2 diabetic rat model. Curr. Eye Res. (2008) 33 885 891.
58. Banday A.A., Lokhandwala M.F. Oxidative stress-induced renal angiotensin AT1 receptor upregulation causes increased stimulation of sodium transporters and hypertension. Am. J. Physiol. Renal Physiol. (2008) 295 698 706.
59. Cheng X.W., Murohara T., Kuzuya M. et al. Superoxide-dependent cathepsin activation is associated with hypertensive myocardial remodeling and represents a target for angiotensin II type 1 receptor blocker treatment. Am. J. Pathol. (2008) 173 358 369.
60. Thomas M.C., Tikellis C., Burns W.M. et al. Interactions between renin angiotensin system and advanced glycation in the kidney. J. Am. Soc. Nephrol. (2005) 16 2976 2984.
61. Koka V., Wang W., Huang X.R., Kim-Mitsuyama S., Truong L.D., Lan H.Y. Advanced glycation end products activate a chymase-dependent angiotensin II-generating pathway in diabetic complications. Circulation (2006) 113 1353 1360.
62. Kawamura H., Kobayashi M., Li Q. et al. Effects of angiotensin II on the pericyte-containing microvasculature of the rat retina. J. Physiol. (2004) 561 671 683.
63. Ruiz-Ortega M., Lorenzo O., Egido J. Angiotensin II increases monocytic chemotactic protein-1 and activates nuclear transcription factor κB and activator protein-1 in cultured mesangial and mononuclear cells. Kidney Int. (2000) 57 2285 2298.
64. Seshiah P.N., Weber D.S., Rocic P., Valppu L., Taniyama Y., Griendling K.K. Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators. Circ. Res. (2002) 91 406 413.
65. Kato H., Suzuki H., Tajima S. et al. Angiotensin II stimulates collagen synthesis in cultured vascular smooth muscle cells. J. Hypertens. (1991) 9 17 22.
66. Otani A., Takagi H., Oh H., Koyama S., Honda Y. Angiotensin II induces expression of the Tie2 receptor ligand, angiopoietin-2, in bovine retinal endothelial cells. Diabetes (2001) 50 867 875.
67. Policha A., Daneshtalab N., Chen L. et al. Role of angiotensin II type 1A receptor phosphorylation, phospholipase D, and extracellular calcium in isoform-specific protein kinase C membrane translocation responses. J. Biol. Chem. (2006) 281 26340 26349.
68. Tilton R.G., Kawamura T., Chang K.C. et al. Vascular dysfunction induced by elevated glucose levels in rats is mediated by vascular endothelial growth factor. J. Clin. Invest. (1997) 99 2192 2202.
69. Chen S., Zivadeh F.N. Vascular endothelial growth factor and diabetic nephropathy. Curr. Diab. Rep. (2008) 8 470 476.
70. Clements R.S. Jr., Morrison A.D., Winegrad A.I. Polyol pathway in aorta: regulation by hormones. Science (1969) 166 1007 1008.
71. Gabriely I., Yang X.M., Cases J.A., Ma X.H., Rossetti L., Barzilai N. Hyperglycemia modulates angiotensinogen gene expression. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2001) 281 795 802.
72. Clermont A., Bursell S.E., Feener E.P. Role of the angiotensin II type 1 receptor in the pathogenesis of diabetic retinopathy: effects of blood pressure control and beyond. J. Hypertens. Suppl. (2006) 24 73 80.
73. Schrijvers B.F., De Vriese A.S., Flyvbjerg A. From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr. Rev. (2004) 25 971 1010.
74. Coppey L.J., Davidson E.P., Rinehart T.W. et al. ACE inhibitor or angiotensin II receptor antagonist attenuates diabetic neuropathy in streptozotocin-induced diabetic rats. Diabetes (2006) 55 341 348.
75. Ha H., Hwang I.-A., Park J.H., Lee H.B. Role of reactive oxygen species in the pathogenesis of diabetic nephropathy. Diab. Res. Clin. Pract. (2008) 825 S42 S45.
76. Liang W., Tan C.Y.R., Ang L., Granville D.J., Wright J.M., Laher I. Ramipril improves oxidative stress-related vascular endothelial dysfunction in db/db mice. J. Physiol. Sci. (2008) 6 405 411.
77. Onozato M.L., Tojo A., Goto A., Fujita T., Wilcox C.S. Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB. Kidney Int. (2002) 61 186 194.
78. Chiarelli F., Di Marzio D., Santilli F. et al. Effects of irbesartan on intracellular antioxidant enzyme expression and activity in adolescents and young adults with early diabetic angiopathy. Diabet. Care (2005) 28 1690 1697.
79. Chen S., Ge Y., Si J., Rifai A., Dworkin L.D., Gong R. Candesartan suppresses chronic renal inflammation by a novel antioxidant action independent of AT1R blockade. Kidney Int. (2008) 74 1128 1138.
80. Izuhara Y., Sada T., Yanagisawa H. et al. A novel sartan derivative with very low angiotensin II Type 1 receptor affinity protects the kidney in Type 2 diabetic rats. Arterioscler. Thromb. Vasc. Biol. (2008) 28 1767 1773.
81. Sugiyama T., Okuno T., Fukuhara M. et al. Angiotensin II receptor blocker inhibits abnormal accumulation of advanced glycation end products and retinal damage in a rat model of type 2 diabetes. Exp. Eye Res. (2007) 85 406 412.
82. Fan Q., Liao J., Kobayashi M. et al. Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice. Nephrol. Dial. Transplant. (2004) 19 3012 3020.
83. Malhotra A., Kang B.P.S., Cheung S., Opawumi D., Meggs L.G. Angiotensin II promotes glucose-induced activation of cardiac protein kinase C isozymes and phosphorylation of Troponin I. Diabetes (2001) 50 1918 1926.
84. Osicka T.M., Yu Y., Lee V., Panagiotopoulos S., Kemp B.E., Jerums G. Aminoguanidine and ramipril prevent diabetes induced increases in protein kinase C activity in glomeruli, retina and mesenteric artery. Clin. Sci. (2001) 100 249 257.
85. Jesmin S., Sakuma I., Hattori Y., Kitabatake A. Role of angiotensin II in altered expression of molecules responsible for coronary matrix remodeling in insulin-resistant diabetic rats. Arterioscler. Thromb. Vasc. Biol. (2003) 23 2021 2026.
86. Feke G.T., Buzney S.M., Ogasawara H. et al. Retinal circulatory abnormalities in type 1 diabetes. Invest. Ophthalmol. Vis. Sci. (1994) 35 2968 2975.
87. Aiello L.P., Clermont A.C., Arora V., Davis M.D., Sheetz M.J., Bursell S.-E. Inhibition of PKC beta by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients. Invest. Ophthalmol. Vis. Sci. (2006) 47 86 92.
88. 1 receptor antagonism normalizes retinal blood flow and acetylcholine-induced vasodiliation in normotensive diabetic rats. Diabetologia (2004) 47 113 123.
89. Iwase M., Doi Y., Goto D. et al. Effect of nicardipine versus enalapril on plasma endothelin-1 in hypertensive patients with type 2 diabetes mellitus. Clin. Exp. Hypertens. (2000) 22 695 703.
90. Gilbert R.E., Kelly D.J., Cox A.J. et al. Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes. Diabetologia (2000) 43 1360 1387.
91. Nagisa Y., Shintani A., Nakagawa S. The angiotensin II receptor antagonist candesartan cilexetil (TCV-116) ameliorates retinal disorders in rats. Diabetologia. (2001) 44 883 888.
92. Coughlan M.T., Thallas-Bonke V., Pete J. et al. Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or redundancy? Endocrinology (2007) 148 886 895.
93. Moravski C.J., Skinner S.L., Stubbs A.J. et al. The renin-angiotensin system influences ocular endothelial cell proliferation in diabetes: transgenic and interventional studies. Am. J. Pathol. (2003) 162 151 160.
94. Ruilope L.M. Angiotensin receptor blockers: RAAS blockade and renoprotection. Curr. Med. Res. Opin. (2008) 24 1285 1293.
95. Burnier M., Zanchi A. Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. J. Hypertens. (2006) 24 11 25.
96. Rossing P., Parving H.-H., de Zeeuw D. Renoprotection by blocking the RAAS in diabetic nephropathy - fact or fiction? Nephrol. Dial. Transplant. (2006) 21 2354 2357.
97. American Diabetes Association. Standards of medical care in diabetes - 2008. Diabet. Care (2008) 31 (Suppl.1) S12 S54.
98. Chaturvedi N., the EUCLID study group. Randomised placebo controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuriaor microalbuminuria. Lancet (1997) 349 1787 1792.
99. Chaturvedi N., Sjolie A.-K., Stephenson J.M. et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet (1998) 351 28 31.
100. Chaturvedi N., Sjølie A.K., Svensson A., for the DIRECT Programme Study Group. The DIabetic Retinopathy Candesartan Trials (DIRECT) Programme, rationale and study design. J. Renin Angiotensin Aldosterone Syst. (2002) 3 255 261.
101. Mauer M., Zinman B., Gardiner R. et al. ACE-I and ARBs in early diabetic nephropathy. J. Renin Angiotensin Aldosterone Syst. (2002) 3 262 269.
102. Stolk R.P., Vingerling J.R., Cruickshank J.K. et al. AdRem project team and ADVANCE management committee. Rationale and design of the AdRem study: evaluating the effects of blood pressure lowering and intensive glucose control on vascular retinal disorders in patients with type 2 diabetes mellitus. Contemp. Clin. Trials (2007) 28 6 17.
103. Chaturvedi N., Porta M., Klein R. et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet (2008) 372 1394 1402.
104. Sjølie A.K., Klein R., Porta M. et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet (2008) 372 1385 1393.
105. Mauer M., Zinman B., Gardiner R. et al. Renal and Retinal effects of enalapril and losartan in Type 1 diabetes. N. Engl. J. Med. (2009) 361 40 51.
106. Bilous R., Chaturvedi N., Sjølie A.K. et al. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann. Intern. Med. (2009) 151 11 20.
107. Beulens J.W., Patel A., Vingerling J.R. et al. Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial. Diabetologia (2009) 52 2027 2036.